Prospect: information for the user
Sitagliptin SUN 25 mg film-coated tablets
Sitagliptin SUN 50 mg film-coated tablets
Sitagliptin SUN 100 mg film-coated tablets
sitagliptin
Read this prospect carefully before starting to take this medicine, as it contains important information for you.
1.What is Sitagliptin SUN and for what it is used
2.What you need to know before starting to take Sitagliptin SUN
3.How to take Sitagliptin SUN
4.Possible adverse effects
5.Storage of Sitagliptin SUN
6.Contents of the package and additional information
Sitagliptina SUN contains the active ingredient sitagliptin, which belongs to a class of medications called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) that reduce blood sugar levels in adult patients with type 2 diabetes mellitus.
This medication helps to increase the levels of insulin produced after a meal and decreases the amount of sugar produced by the body.
Your doctor has prescribed this medication to help you reduce your blood sugar, which is too high due to your type 2 diabetes. This medication may be used alone or in combination with other medications (insulin, metformin, sulfonylureas, or thiazolidinediones) that reduce blood sugar, and that you may already be taking for your diabetes along with a diet and exercise program.
What is type 2 diabetes?
Type 2 diabetes is a disease that consists of your body not producing enough insulin, and the insulin it produces not working as well as it should. Your body may also produce too much sugar. When this happens, sugar (glucose) accumulates in the blood. This can cause serious medical problems, such as heart disease, kidney disease, blindness, and amputation.
Do not take Sitagliptina SUN
Warnings and precautions
Cases of pancreatitis have been reported in patients treated with sitagliptin (see section 4).
If you notice blisters on your skin, it may be a sign of a condition called bullous pemphigoid. Your doctor may ask you to stop taking Sitagliptina SUN.
Inform your doctor if you have or have had:
It is unlikely that this medication will cause low blood sugar because it does not act when blood sugar levels are low. However, when this medication is used in combination with a medication that contains a sulfonylurea or with insulin, low blood sugar (hypoglycemia) may occur. Your doctor may reduce the dose of your sulfonylurea or insulin medication.
Children and adolescents
Children and adolescents under 18 years old should not use this medication. It is not effective in children and adolescents aged 10 to 17 years. The safety and efficacy of this medication in children under 10 years old are unknown.
Use of Sitagliptina SUN with other medications
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
Particularly, inform your doctor if you are taking digoxin (a medication used to treat irregular heartbeat and other heart problems). Your digoxin level in the blood may need to be checked if you are taking sitagliptin.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before using this medication. This medication should not be taken during pregnancy.
The safety of this medication during breastfeeding is unknown. Do not take this medication if you are breastfeeding or plan to breastfeed.
Driving and operating machinery
The influence of this medication on the ability to drive or operate machinery is negligible. However, dizziness and somnolence have been reported, which may affect your ability to drive or operate machinery.
Additionally, taking this medication with medications called sulfonylureas or with insulin may cause hypoglycemia, which may affect your ability to drive and operate machinery or work safely without support.
Sitagliptina SUN contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially "sodium-free".
Sitagliptina SUN contains hydrogenated castor oil
It may cause stomach discomfort and diarrhea.
Follow exactly the administration instructions for this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
The usual recommended dose is:
-one film-coated tablet of 100 mg
-once a day
-by mouth
If you have kidney problems, your doctor may prescribe lower doses (such as 25 mg or 50 mg).
You can take this medication with or without food.
Your doctor may prescribe this medication alone or with other medications that also lower blood sugar.
Diet and exercise can help your body use blood sugar better. It is important that you follow the diet and exercise recommended by your doctor while taking sitagliptina.
If you take more Sitagliptina SUN than you should
If you take more doses of this medication than prescribed, contact your doctor immediately.
If you forget to take Sitagliptina SUN
If you forget a dose, take it as soon as you remember. If you do not remember until the time of the next dose, then skip the missed dose and continue with your regular schedule. Do not take a double dose of this medication.
If you interrupt treatment with Sitagliptina SUN
Continue taking this medication as long as your doctor prescribes it for you to continue helping to control your blood sugar. You should not stop taking this medication without first consulting your doctor.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
STOP taking sitagliptin and see your doctor immediately if you notice any of the following serious side effects:
If you have a severe allergic reaction (unknown frequency), including skin rash, urticaria, blisters on the skin/skin peeling and swelling of the face, lips, tongue, and throat that can cause difficulty breathing or swallowing, stop taking this medicine and consult your doctor immediately. Your doctor will prescribe a medicine to treat the allergic reaction and change the medicine for diabetes treatment.
Some patients experienced the following side effects after adding sitagliptin to metformin treatment:
Frequent (can affect up to 1 in 10 people): low blood sugar, nausea, flatulence, vomiting
Infrequent (can affect up to 1 in 100 people): stomach pain, diarrhea, constipation, drowsiness.
Some patients experienced different types of stomach discomfort when they started taking sitagliptin and metformin together (classified as frequent).
Some patients experienced the following side effects while taking sitagliptin with a sulfonylurea and metformin:
Very frequent (can affect more than 1 in 10 people): low blood sugar Frequent: constipation
Some patients experienced the following side effects while taking sitagliptin and pioglitazone:
Frequent: flatulence, swelling of hands or feet
Some patients experienced the following side effects while taking sitagliptin with pioglitazone and metformin:
Frequent: swelling of hands or feet
Some patients experienced the following side effects while taking sitagliptin with insulin (with or without metformin):
Frequent: flu
Infrequent: dry mouth
Some patients experienced the following side effects while taking sitagliptin only during clinical trials, or during use after approval alone and/or with other diabetes medicines:
Frequent: low blood sugar, headache, upper respiratory tract infection, congestion or nasal mucosity and sore throat, arthritis, arm or leg pain Infrequent: dizziness, constipation, itching
Rare: reduction in platelet count
Unknown frequency: kidney problems (which sometimes require dialysis), vomiting, joint pain, muscle pain, back pain, interstitial lung disease, bullous pemphigoid (a type of blister on the skin)
Reporting of side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the national notification system included in theAppendix V.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister pack and on the carton after CAD. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medications should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. By doing so, you will help protect the environment.
Composition of Sitagliptin SUN
orEach Sitagliptin SUN 25 mg film-coated tablet contains
sitagliptin fumarate equivalent to 25 mg of sitagliptin.
or Each Sitagliptin SUN 50 mg film-coated tablet contains sitagliptin fumarate equivalent to 50 mg of sitagliptin.
or Each Sitagliptin SUN 100 mg film-coated tablet contains sitagliptin fumarate equivalent to 100 mg of sitagliptin.
orCore tablet: calcium phosphate (E341), crospovidone type A (E1202), hydrogenated castor oil, glycerol dibehenate, magnesium stearate (E470b).
or Coating: hypromellose 2910/5 (E464), titanium dioxide (E171), macrogol 6000 (E1521), talc (E553b), iron oxide red (E172) and iron oxide yellow (E172).
Appearance of the product and contents of the pack
The film-coated tablets of Sitagliptin SUN are packaged in blisters of PA/Alu/PE + desiccant/HDPE/Alu. They are available in packs containing 28, 56 or 98 film-coated tablets.
The film-coated tablets of Sitagliptin SUN are also available in packs containing a HDPE bottle with 90 film-coated tablets.
Only some pack sizes may be marketed.
Marketing Authorisation Holder
Sun Pharmaceutical Industries Europe B.V.
Polarisavenue 87
2132JH Hoofddorp
Netherlands
Responsible Person
Sun Pharmaceutical Industries Europe B.V.
Polarisavenue 87
2132JH Hoofddorp
Netherlands
Terapia S.A.
Str. Fabricii nr. 124
Cluj-Napoca, 400632
Romania
For further information about this medicinal product, please contact the local representative of the marketing authorisation holder:
Deutschland
Sun Pharmaceuticals Germany GmbH
Hemmelrather Weg 201
51377 Leverkusen
Germany
Phone +49 214 403 990
España
Sun Pharma Laboratorios, S.L.
Rambla de Catalunya 53-55
08007 Barcelona
Spain
Phone +34 93 342 78 90
France
Sun Pharma France
31 rue des Poissonniers
92200 Neuilly-sur-Seine France
Phone +33 1 41 44 44 50
Italia
Sun Pharma Italia Srl
Viale Giulio Richard, 1
20143 Milano
Italy
Phone +39 02 33 49 07 93
Polska
Ranbaxy (Poland) Sp. z o. o.
ul. Idzikowskiego
16 00-710 Warszawa Polska
Phone +48 22 642 07 75
România
Terapia S.A.
Str. Fabricii nr 124
Cluj-Napoca, Judetul Cluj
Romania
Phone +40 (264) 501 500
Last update of this leaflet:
The detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.